Conmed (CNMD) Up 7.1% Since Last Earnings Report: Can It Continue?

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Aug 28, 2026

CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Wells Fargo 21st Annual Healthcare Conference, which is being held September 8-10, 2026 at the Encore Boston Harbor in Everett, MA. Management will participate in a fireside chat on Wednesday, September 9th at 1:30 p.m. Eastern Time. A live audio webcast of the fireside chat will be accessible under the “Events” section of the company's investor relations website: https://www.conmed.com/en/inv.

Business Wire • Aug 26, 2026

CONMED Corporation: Organic Growth Is Masked By Divestitures

Conmed's headline growth appeared flat at $343 million in the last quarter, but organic growth actually increased by 6%, with the leading segment being the orthopedic surgery business. Growth was offset by the divestiture of the GI business; as a result, growth metrics look poor with a quant rating of F and below the sector growth. When I adjust for organic growth, impressive profitability, and a buyback story, Conmed stock looks highly undervalued below the sector multiple. and I am rating it a buy.

Seeking Alpha • Aug 18, 2026

Here's Why You Should Retain CONMED Stock in Your Portfolio Now

CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.

Zacks Investment Research • Aug 17, 2026

Is CNMD a Buy Now as Low Valuation Meets Persistent Execution Risk?

CNMD's low valuation and improved earnings outlook strengthen its appeal, but cash-flow pressure and execution risks keep the buy case measured.

Zacks Investment Research • Aug 17, 2026

Can CONMED's Raised 2026 EPS Outlook Reinforce Its Growth Momentum?

CONMED raised its 2026 adjusted EPS outlook after a strong second quarter, but slower organic growth and higher financing costs keep the setup mixed.

Zacks Investment Research • Aug 17, 2026

CNMD Jumps 16% in a Month as Investors Assess Whether It Can Last

CNMD's 16% monthly rally is backed by stronger growth, margin gains and raised earnings guidance, but cash-flow and execution risks remain.

Zacks Investment Research • Aug 17, 2026

CONMED Corporation (CNMD) Q2 2026 Earnings Call Transcript

CONMED Corporation (CNMD) Q2 2026 Earnings Call Transcript

Seeking Alpha • Jul 30, 2026

CONMED Q2 Earnings and Revenues Beat Estimates, Gross Margin Expands

CNMD's Q2 earnings and revenues beat estimates, while margin growth and solid international sales support a higher 2026 EPS outlook.

Zacks Investment Research • Jul 30, 2026

CONMED Q2 Earnings Call Highlights

CONMED NYSE: CNMD reported second-quarter 2026 net sales of $343.5 million, up 0.3% on a reported basis but down 0.5% in constant currency. Organic sales, which exclude the company's exited gastroenterology product offerings, rose 6% year over year and modestly exceeded management's expectations.

MarketBeat • Jul 30, 2026